Jco precision oncology.

PURPOSE We conducted this systematic review to evaluate the clinical outcomes associated with molecular tumor board (MTB) review in patients with cancer. METHODS A systematic search of PubMed was performed to identify studies reporting clinical outcomes in patients with cancer who were reviewed by an MTB. To be included, studies had to report clinical outcomes, including clinical benefit ...Purpose A long natural history and a predominant osseous pattern of metastatic spread are impediments to the adoption of precision medicine in patients with prostate cancer. To establish the feasibility of clinical genomic profiling in this disease, we performed targeted deep sequencing of tumor and normal DNA from patients with …WebDOI: 10.1200/PO.22.00604 JCO Precision Oncology no. 7 (2023) e2200604. Published online July 12, 2023. PMID: 37437231. Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies Akram Mesleh Shayeb, MD 1. x. Akram Mesleh Shayeb. Search for articles …The introduction of NGS assays has allowed the cancer genome to be systematically studied, providing oncologists with more comprehensive, precise, predictive, prognostic, and diagnostic information. 2 NGS-based gene panel tests have successfully identified driver mutations in lung cancers, 3,4 colorectal cancer, 5 and breast cancer, 3 which in turn has resulted in the development and use of ...

A precision haircut is a style using techniques that create straight, dramatic lines and clean angles. Vidal Sassoon was the pioneer of precision haircutting, with the original philosophy of creating haircuts based on a client’s bone struct...Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision …28 Mar 2023 ... Dr Matteo Lambertini speaks to ecancer about the present and future of precision oncology in breast cancer. He begins by highlighting the ...

Precision oncology, where patients are given therapies on the basis of their genomic profile and disease trajectory, is rapidly evolving to become a pivotal part of cancer management, supported by the approval of many biomarker-matched targeted therapies and cancer immunotherapies by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). 1 Driven by recent advances in ...

JCO precision oncology Machine Name 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration.DOI: 10.1200/PO.16.00066 JCO Precision Oncology - published online June 27, 2017WebJCO Precision Oncology (JCO PO) is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics-driven clinical care of patients with cancer. DOI: 10.1200/PO.20.00534 JCO Precision Oncology no. 5 (2021) 771-778. Published online May 3, 2021. Published online May 3, 2021. Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case ReportWebJul 19, 2023 · In this prospective, case-control study, we assessed the performance of a blood-based multi-cancer detection test to detect cancer and predict the origin of the cancer signal in individuals with symptoms suspicious for cancer.

This is the context motivating the publication by Stetson et al 10 in JCO Precision Oncology. The authors sent aliquots of plasma to four commercial Clinical Laboratory Improvement Amendments–certified laboratories for plasma NGS and compared this to NGS performed on matched tumor and normal tissue at Foundation Medicine. …

PURPOSE In the two-cohort phase II KEYNOTE-086 study (ClinicalTrials.gov identifier: NCT02447003), first-line and second-line or later pembrolizumab monotherapy demonstrated antitumor activity in metastatic triple-negative breast cancer (mTNBC; N = 254). This exploratory analysis evaluates the association between prespecified molecular biomarkers and clinical outcomes. METHODS Cohort A ...

Jul 6, 2023 · Pancreatic cancer remains one of the leading causes of cancer-related death, with an estimated 64,050 new cases and 50,550 deaths in the United States in 2023. 1 Among various malignancies, pancreatic cancer is considered highly aggressive and exhibits one of the lowest 5-year survival rates at 10%. 1 Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of cases of pancreatic ... 15 Sept 2023 ... 5. Johnson A , Khotskaya YB , Brusco L , et al. Clinical use of precision oncology decision support. JCO Precis Oncol. 2017. doi:10.1200 ...Jun 25, 2020 · PURPOSE The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known to be drug targets. Results in a cohort of patients with non–small-cell lung cancer (NSCLC) with CDKN2A alterations treated with palbociclib are ... Mar 9, 2022 · This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: MolecularMatch, Lutris, Iylon, Frontier Medicines DOI: 10.1200/PO.20.00472 JCO Precision Oncology no. 5 (2021) 1312-1324. Published online August 19, 2021. Published online August 19, 2021. Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor SamplesDOI: 10.1200/PO.18.00325 JCO Precision Oncology - published online June 13, 2019DOI: 10.1200/PO.21.00011 JCO Precision Oncology no. 5 (2021) 1687-1698. Published online November 3, 2021. Published online November 3, 2021. Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary

DOI: 10.1200/PO.23.00092 JCO Precision Oncology no. 7 (2023) e2300092. Published online July 6, 2023. PMID: 37410975. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness ...Feb 21, 2022 · DOI: 10.1200/PO.21.00383 JCO Precision Oncology no. 6 (2022) e2100383. Published online February 21, 2022. Published online February 21, 2022. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy PURPOSE The DecisionDx-Melanoma 31-gene expression profile (31-GEP) test is validated to classify cutaneous malignant melanoma (CM) patient risk of recurrence, metastasis, or death as low (class 1A), intermediate (class 1B/2A), or high (class 2B). This study aimed to examine the effect of 31-GEP testing on survival outcomes and confirm the prognostic ability of the 31-GEP at the population ...JCO Oncology Practice (JCO OP) publishes impactful information and insights to keep oncology ... JCO Precision Oncology is a peer-reviewed, online-only journal ...JCO Precision Oncology ( JCO PO) is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer.

Jun 1, 2023 · Diagnosis & treatment of ercc3-mutant cancer US20210137850A1. Other Relationship: AnaNeo Therapeutics. Jinru Shia. Consulting or Advisory Role: PAIGE.AI. Zsofia K. Stadler. This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.

Journal of Clinical Oncology JCO Oncology Practice JCO Global Oncology JCO Clinical Cancer Informatics JCO Precision Oncology. Publications. ASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post Oct 23, 2019 · DOI: 10.1200/PO.19.00115 JCO Precision Oncology - published online October 23, 2019 DOI: 10.1200/PO.22.00531 JCO Precision Oncology no. 7 (2023) e2200531. Published online May 4, 2023. PMID: 37141549. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis Lorenzo Gerratana, MD 1. x. Lorenzo Gerratana. Search for articles by this …JCO Oncology Practice (JCO OP) publishes impactful information and insights to keep oncology ... JCO Precision Oncology is a peer-reviewed, online-only journal ...The analysis focuses on the independent and cumulative impacts of gaps occurring during seven steps of the precision oncology pathway, from diagnosis to treatment. Results: For every 1,000 patients in the study cohort, 497 (49.7%) are lost to precision oncology because of factors associated with getting biomarker test results. Among the 503 of ...WebApr 1, 2021 · Multicancer Screening: One Size Does Not Fit All. Cancer is the second leading cause of death in the United States, 1 and early detection represents one of the best hopes for reducing cancer-associated morbidity and mortality. However, current screening strategies are limited by suboptimal adherence, low sensitivity for early-stage disease ... DOI: 10.1200/PO.20.00178 JCO Precision Oncology no. 5 (2021) 44-50. Published online January 8, 2021. Published online January 8, 2021. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 AlterationsPancreatic cancer remains one of the leading causes of cancer-related death, with an estimated 64,050 new cases and 50,550 deaths in the United States in 2023. 1 Among various malignancies, pancreatic cancer is considered highly aggressive and exhibits one of the lowest 5-year survival rates at 10%. 1 Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of cases of pancreatic ...Precision fabrication is a critical process in various industries, including manufacturing, construction, and automotive. Whether it’s building structures, creating intricate metal designs, or repairing equipment, welding plays a crucial ro...

DOI: 10.1200/PO.20.00241 JCO Precision Oncology no. 5 (2021) 93-102. Published online January 11, 2021. PMID: 34994593. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer ...

DOI: 10.1200/PO.21.00141 JCO Precision Oncology no. 5 (2021) 1270-1280. Published online August 11, 2021. Published online August 11, 2021. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types

PURPOSE Next-generation sequencing (NGS) of tumor and germline DNA is foundational for precision oncology, with rapidly expanding diagnostic, prognostic, and therapeutic implications. Although few question the importance of NGS in modern oncology care, the process of gathering primary molecular data, integrating it into electronic health …PURPOSE CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program that uses genomics and transcriptomics to guide therapeutic decisions in the clinical management of metastatic breast cancer. Herein, we report our single-center experience and ...PURPOSE The adoption of precision medicine (PMed) depends on the critical curation of data and interpretation of genomic results. Herein, we sought to study the effect of a coordinated multidisciplinary program to assess results in a community cancer center clinic. METHODS In a retrospective review from July 2018 to July 2021, we analyzed the implementation of a multidisciplinary PMed program ...DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017DOI: 10.1200/PO.20.00110 JCO Precision Oncology no. 4 (2020) 823-824. Published online July 16, 2020. PMID: 35050756. Remarkable Response to Erdafitinib in Metastatic Lung Adenocarcinoma With FGFR Fusion Samuel A. Urrutia Argueta, MD 1. x. Samuel A. Urrutia Argueta. Search for articles by this author ...DOI: 10.1200/PO.19.00399 JCO Precision Oncology no. 4 (2020) 370-381. Published online April 21, 2020. PMID: 32462107DOI: 10.1200/PO.22.00694 JCO Precision Oncology no. 7 (2023) e2200694. Published online September 1, 2023. PMID: 37656949. Dynamic Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer Milena Urbini, PhD 1. x. Milena Urbini. Search for articles by this author ...DOI: 10.1200/PO.21.00002 JCO Precision Oncology no. 6 (2022) e2100002. Published online January 6, 2022. PMID: 35005994Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision …PURPOSE CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program that uses genomics and transcriptomics to guide therapeutic decisions in the clinical management of metastatic breast cancer. Herein, we report our single-center experience and ...

DOI: 10.1200/PO.22.00580 JCO Precision Oncology no. 7 (2023) e2200580. Published online March 23, 2023. PMID: 36952646. Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study Trisha Larkin, MD 1, 2. x. Trisha Larkin. …WebThe field of behavioral economics recognizes that humans make decisions within the constraints of bounded rationality because of time and cognitive limits such as those observed with precision oncology. 1 This results in the use of heuristics (such as race), which may in turn increase individuals' reliance on cognitive biases (including …DOI: 10.1200/PO.20.00516 JCO Precision Oncology no. 5 (2021) 653-663. Published online April 13, 2021. Published online April 13, 2021. MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing ConsiderationsInstagram:https://instagram. lucdcentral japan railwaybuy pointbest dental insurance arkansas DOI: 10.1200/PO.20.00534 JCO Precision Oncology no. 5 (2021) 771-778. Published online May 3, 2021. Published online May 3, 2021. Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case ReportWebDOI: 10.1200/PO.18.00414 JCO Precision Oncology no. 4 (2020) 557-569. Published online June 1, 2020. PMID: 32923885. Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients Jingyu Cao, MD 1. x. Jingyu Cao. Search for articles by this author; Jing ... top us regulated forex brokershow to set up an ameritrade account DOI: 10.1200/PO.18.00414 JCO Precision Oncology no. 4 (2020) 557-569. Published online June 1, 2020. PMID: 32923885. Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients Jingyu Cao, MD 1. x. Jingyu Cao. Search for articles by this author; Jing ...Acknowledgment of Reviewers, 2023. Peer review is at the core of scientific progress. It is through the careful critique of peer reviewers that manuscripts are scrutinized, evaluated, and improved. An article that has been peer reviewed is determined to be valid and worthy of publication. These peer-reviewed manuscripts are a critical component ... best online bank apps DOI: 10.1200/PO.18.00401 JCO Precision Oncology - published online June 20, 2019 Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non–Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results6 Nov 2023 ... jpg. Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer ...PURPOSE HER2 is a critical gene that drives various solid tumors in addition to those of breast cancer. For example, HER2 plays a role in non–small-cell lung cancer (NSCLC). Overexpression, amplification, and point mutations in HER2 have been described in patients with NSCLC; however, the potential roles of these alterations remain unclear. METHODS We summarize the evidence regarding the ...